Cempra, Inc. (NASDAQ:CEMP) has received an average rating of “Hold” from the nineteen research firms that are covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $8.70.

CEMP has been the topic of several recent research reports. ValuEngine cut Cempra from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Vetr cut Cempra from a “strong-buy” rating to a “buy” rating and set a $3.95 price objective on the stock. in a report on Monday, March 6th. Jefferies Group LLC reaffirmed a “hold” rating and set a $3.00 price objective on shares of Cempra in a report on Thursday, May 25th. Zacks Investment Research cut Cempra from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd. Finally, Robert W. Baird reaffirmed an “underperform” rating on shares of Cempra in a report on Tuesday, March 28th.

Shares of Cempra (NASDAQ CEMP) opened at 4.575 on Monday. The stock’s market capitalization is $240.20 million. The company has a 50-day moving average of $4.02 and a 200-day moving average of $3.94. Cempra has a 52 week low of $2.55 and a 52 week high of $26.95.

Cempra (NASDAQ:CEMP) last posted its quarterly earnings results on Friday, April 28th. The biotechnology company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.16. Cempra had a negative return on equity of 56.60% and a negative net margin of 551.45%. The business had revenue of $4.87 million during the quarter, compared to the consensus estimate of $3.55 million. During the same period in the prior year, the company posted ($0.61) EPS. On average, analysts anticipate that Cempra will post ($1.06) EPS for the current year.

Several institutional investors have recently bought and sold shares of CEMP. Asset Management One Co. Ltd. purchased a new position in Cempra during the first quarter worth about $106,000. Dimensional Fund Advisors LP purchased a new position in Cempra during the fourth quarter worth about $111,000. UBS Asset Management Americas Inc. purchased a new position in Cempra during the first quarter worth about $140,000. Levin Capital Strategies L.P. increased its position in Cempra by 56.5% in the first quarter. Levin Capital Strategies L.P. now owns 49,349 shares of the biotechnology company’s stock worth $185,000 after buying an additional 17,825 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Cempra during the first quarter worth about $187,000. 49.36% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/07/03/cempra-inc-nasdaqcemp-given-consensus-rating-of-hold-by-analysts.html.

About Cempra

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Analyst Recommendations for Cempra (NASDAQ:CEMP)

Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.